Etripamil, sold under the brand name Cardamyst, is a medication used for the treatment of paroxysmal supraventricular tachycardia. It is a calcium channel blocker. It is used as a nasal spray.
Etripamil was approved for medical use in the United States in December 2025.
Medical uses Etripamil is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.
Pharmacology Mechanism of action Etripamil is a voltage-dependent L-type calcium channel inhibitor.
Society and culture Legal status Etripamil was approved for medical use in the United States in December 2025.
Names Etripamil is the international nonproprietary name.
Etripamil is sold under the brand name Cardamyst.
References
External links